Utilization of Glucagon-Like Peptide-1 Receptor Agonist at the Time of Total Hip Arthroplasty for Patients Who Have Morbid Obesity
Billy I. Kim, Tyler Khilnani, Scott M. LaValva, Susan M. Goodman, Alejandro González Della Valle, Gwo‐Chin Lee
Topics & Concepts
AgonistGlucagon-like peptide-1MedicineMorbid obesityTotal hip arthroplastyObesityReceptorInternal medicineGlucagon-like peptide 1 receptorDiabetes mellitusEndocrinologySurgeryType 2 diabetesWeight lossBariatric Surgery and OutcomesTotal Knee Arthroplasty OutcomesHyperglycemia and glycemic control in critically ill and hospitalized patients